Le Lézard
Classified in: Health
Subjects: POL, TRD, AVO

3 Reasons Innovation Depends On Strong IP Protections in the TPP



WASHINGTON, June 16, 2015 /PRNewswire-USNewswire/ -- As Congress continues to debate Trade Promotion Authority (TPA), it is important to keep in mind why the Trans-Pacific Partnership (TPP) ? the largest trade deal in history ? can and should help propel the United States (U.S.) into a new era of innovation and productivity in biopharmaceutical manufacturing.

3 Reasons Innovation Depends on Strong IP Protections in the TPP

Our industry's core mission is the discovery of new treatments and cures to help patients live longer, healthier lives. Below are three important facts to keep in mind about why upholding strong intellectual property (IP) protections as part of TPP are vital to the continued discovery and delivery of medicines for the world's patients:

#1. Creating life-saving medicines requires significant investment and resources. 
New medicines are the result of up to 15 years of complex research and development at an average cost of $2.6 billion. The U.S. and other nations must encourage and incentivize the innovation that has the potential to propel today's research into tomorrow's most cutting-edge treatments and cures.

#2. For medical innovation to continue, the TPP must uphold the strong IP protections that currently exist in the U.S. 
The important role of IP ? including a 12-year data protection period for biologics ? is not a new idea. In fact, it was codified in the Affordable Care Act, endorsed by a strong, bipartisan majority in Congress. 

#3. The evidence is overwhelming that the U.S. model works. 
Strong protection of IP is a catalyst for the creation of new medicines for the world's patients. In too many countries, patient access to medicines are stymied not by strong IP protections, but dynamics like poor infrastructure, lack of investment and high tariffs.  The robust IP protections afforded in the United States have helped foster a system whereby the U.S. dominates the pipeline of new drugs in development and, in turn, where generics comprise a healthy 85 percent-plus of the market.

As PhRMA CEO John Castellani notes this week in Morning Consult, we must continue to create an environment ripe for investment today to unlock the promising science of tomorrow. 

This post originally appeared here: http://catalyst.phrma.org/3-reasons-innovation-depends-on-strong-ip-protections-in-the-tpp.

Contact: Tina Stow; 202-835-3460; newsroom@phrma.org

Pharmaceutical Research and Manufacturers of America.

Photo - http://photos.prnewswire.com/prnh/20150616/223597

Logo - http://photos.prnewswire.com/prnh/20091027/PHRMALOGO

 

SOURCE Pharmaceutical Research and Manufacturers of America


These press releases may also interest you

at 03:00
PARK CITY, Utah and LOS ANGELES, Jan. 21, 2018 /PRNewswire-PRWeb/ -- SAFE SPACE Celebrates Thought Leaders, Influencers and Activists Working to Empower Women to Respect Themselves, Protect Themselves, Be Safe and Feel Safe. SAFE Movement announces...

20 jan 2018
Princeton Identity Inc., provider of the fastest, simplest and most secure biometric security system on the market, today announced the deployment of its Access500etm identity management kiosk module within the Dubai International Airport (DXB)....

20 jan 2018
Array BioPharma Inc. and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab,...

20 jan 2018
The 15th Guignolée du Dr Julien ended this week with a total of $1,744,000 raised in support of the Fondation du Dr Julien's three centres of expertise (CSPC Hochelaga-Maisonneuve, CSPC Côte-des-Neiges and Garage à musique). This amount represents...

20 jan 2018
Taiho Oncology, Inc. and Servier today announced clinical data for LONSURF® (trifluridine and tipiracil) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluropyrimidine-, oxaliplatin- and...

20 jan 2018
Top 10 Jungle, a provider of slick digital content and online product reviews for the medical alert industry, explains to seniors and medical alert customers how a government shutdown can affect them. Top 10 Jungle recently released its 2018...




News published on 16 june 2015 at 17:35 and distributed by: